Ligand Pharmaceuticals Incorporated is a biopharmaceutical royalty company that acquires and creates diversified royalty streams from high-value medicines. The company deploys capital through royalty purchases, development-stage financing arrangements, and acquisitions of companies or assets with embedded royalty rights. Ligand operates two infrastructure-light, royalty-generating platform technologies, Captisol and NITRICIL, which are licensed to biopharmaceutical partners for drug development. The company’s portfolio includes commercial-stage royalty assets in therapeutic areas such as cancer, kidney disease, diabetes, and rare conditions. Notable royalty interests include Filspari, Ohtuvayre, Capvaxive, Vaxneuvance, Rylaze, Pneumosil, Teriparatide, Zelsuvmi, and Qarziba. Ligand has completed strategic acquisitions of Pharmacopeia, Metabasis, Vernalis, Pfenex, Novan, and Apeiron to access embedded royalty rights and late-stage assets. The company partners with biopharmaceutical manufacturers to leverage their capabilities in late-stage development, regulatory execution, and commercialization while maintaining a lean corporate cost structure.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Asset Management Homepage ligand.com
Sector Financial Services IR page investor.ligand.com/overview/default.aspx
Tags
biopharmaceutical royalties, royalty aggregation, drug development financing, ip platform licensing, captisol technology, nitricil technology, oncology, nephrology, endocrinology, rare diseases, Captisol, NITRICIL, Filspari, Ohtuvayre, Capvaxive, Vaxneuvance, Rylaze, Pneumosil, Teriparatide, Zelsuvmi, Qarziba, Ryjunea, Pharmacopeia, Metabasis, Vernalis, Pfenex, Novan, Apeiron, Primrose Bio, Pelthos, OmniAb, Pelican Expression Technology
Press page —

Metrics

Valuation  
Market cap $ 6.432B
Market cap (USD) $ 6.432B
P/E 126.61
PEG —
P/BV 6.69
P/S 25.34
P/OCF 70.66
P/FCF 70.97
Dividend yield —
Turnover / mcap —
Returns  
ROE 13.5%
ROI 8.5%
ROIC 2.2%
Profit margin 46.4%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 117.3%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 46
Quality score 5.6%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001
Revenue 268.087M 167.133M 131.314M 196.245M 277.133M 186.419M 120.282M 251.453M 141.102M 108.973M 71.914M 64.538M 48.973M 31.388M 30.037M 23.538M 38.94M 27.315M — 140.96M 123.01M 163.512M 141.14M 96.64M 76.341M
Net profit 124.453M -4.032M 52.154M -33.361M 57.138M -2.985M 629.302M 143.321M 12.556M -1.636M 257.305M 12.024M 11.42M -527K 10.176M -10.373M -1.948M -98.114M 281.688M -31.743M -36.399M -45.141M -37.462M -32.596M -42.995M
Free cash flow 48.907M 95.226M 46.056M 119.927M 70.037M 50.128M -31.889M 193.172M 91.412M 61.151M 41.634M 20.56M 20.313M -434K -1.25M -27.137M -34.323M -21.12M -98.167M -140.304M 5.769M 2.15M -2.509M -28.273M -21.88M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001
Share price 189.07 107.15 71.42 66.8 154.46 99.45 104.29 135.7 136.93 101.61 108.42 53.21 52.6 20.73 10.59 1.6 2.15 1.98 4.28 11.26 — — — — —
Price performance 12m 0.76 0.5 0.07 -0.57 0.55 -0.05 -0.23 -0.01 0.35 -0.06 1.04 0.01 1.54 0.96 5.62 -0.26 0.09 -0.54 -0.62 — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 14.7M 25.6M 55.9M 30.4M 56.8M 85.5M 30.4M 32.9M 38.4M 59.6M
↳ YoY growth +138.2% +74.1% +118.2% -45.6% +87.1% +50.3% -64.4% +8.2% +16.6% +55.3%
↳ 5y CAGR +19.2% +41.0% +90.6% +19.2% +55.9% +42.2% +3.5% -10.0% +4.8% +1.0%
Lease liabilities (USD) — — 0.00 11.2M 14.2M 17.7M 11.1M 6.18M 7.15M 5.35M
Cash and deposits (USD) 18.8M 20.6M 117M 71.5M 47.6M 19.5M 45M 23M 72.3M 175M
Intangible assets (USD) 205M 229M 220M 210M 595M 551M 342M 300M 267M 225M
Right-of-use assets (USD) — — 0.00 10.4M 6.89M 16.5M 10.9M 6.06M 6.91M 5.15M
Cash flow detail
Operating cash flow (USD) 63M 93.6M 194M -29.3M 54.6M 78.8M 138M 49.6M 97M 49.4M
Purchases of property, plant and equipment (USD) -1.85M -2.16M -887,000 -2.55M -4.46M -8.76M -17.9M -3.52M -1.82M -452,000
Change in receivables (cash effect) (USD) -8.53M -8.36M -29.5M 25.5M -26.1M -28.6M 55.3M -2.6M -6.46M -21.7M
Change in inventories (cash effect) (USD) -244,000 -843,000 -2.56M -2.06M -17.8M -427,000 12.1M -10.9M 9.62M 4.99M
Change in payables (cash effect) (USD) -2.37M -1.71M -4.54M -6.83M -1.25M 2.81M -3.34M -4.7M 13.9M 5.88M
Share buybacks (cash effect) (USD) -3.9M -1.97M -123M -453M -78M 0.00 0.00 0.00 0.00 -15M
Interest paid (cash effect) (USD) -1.84M -1.84M -1.51M -5.83M -4.46M -3.03M -1.43M -288,000 -263,000 -321,000
Income taxes paid (cash effect) (USD) -38,000 -157,000 -341,000 -104M -2.13M -3.72M -11.6M -8.77M -19.2M -7.8M
Share-based compensation (USD) 18.9M 24.9M 20.8M 24.5M 30.7M 38.8M 60.3M 25.7M 41.1M 46.8M
Operating cash flow before change in receivables (USD) 71.5M 102M 224M -54.8M 80.6M 107M 82.5M 52.2M 104M 71.1M
Free cash flow (OCF - PPE - intangibles) (USD) 61.2M 91.4M 193M -31.9M 50.1M 70M 120M 46.1M 95.2M 48.9M
Income detail
Research and development expense (USD) 21.2M 26.9M 27.9M 55.9M 59.4M 69M 36.1M 24.5M 21.4M 81.2M
↳ 5y CAGR +15.6% +20.0% +24.6% +35.8% +34.7% +26.6% +6.1% -2.5% -17.5% +6.5%
Total comprehensive income (USD) -3.8M 12.3M 142M 630M -3.57M 57M -33.4M 52.3M -9.16M 139M
Comprehensive income to owners (USD) -3.8M 12.3M 142M 630M -3.57M 57M -33.4M 52.3M -9.16M 139M
Reported Feb 28, 2017 Mar 1, 2018 Aug 8, 2019 Feb 27, 2020 Feb 24, 2021 Feb 28, 2022 Feb 28, 2023 Feb 27, 2026 Feb 27, 2026 Feb 27, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Ligand Reports Third Quarter 2026 Financial Results Bull 4 Bear 0 Results

October 29, 2026

Third-quarter royalty revenue up 51% year-over-year to $70.3 million

Raises Full-Year 2026 Adjusted Diluted EPS Guidance to $9.50 to $9.75, from $9.00 to $9.50__1_; Reaffirms Revenue Guidance_

Conference call begins at 8:30 a.m. Eastern Time today

JUPITER, Fla., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and nine months ended September 30, 2026, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Eastern Time to discuss the results and answer questions.

“Ligand delivered another strong quarter, with royalty revenue growing 51% year-over-year, driven by contribution from the XOMA portfolio and continued commercial momentum across our key royalty assets, including Filspari,” said Todd Davis, CEO of Ligand. “We also continued to put capital to work in differentiated assets, acquiring a royalty interest in Santen’s Ryjunea and entering into a structured financing agreement with AvenCell Therapeutics to advance its next-generation CAR-T pipeline. With a strong balance sheet and a portfolio of over 200 assets, we are well positioned to continue executing our royalty aggregation strategy, and we look forward to sharing an updated five-year outlook at our investor day on December 8th.”

Financial Results

Third Quarter 2026 Financial Results

Third-quarter 2026 results reflect continued strength in the royalty business, with royalty revenue increasing 51% year-over-year to $70.3 million, compared with $46.6 million for the prior-year period. Royalties accounted for 89% of total revenues and income in the quarter, with growth driven by the newly acquired XOMA assets and continued momentum across Ligand’s key commercial portfolio, including Travere Therapeutics’ Filspari and Merck’s Ohtuvayre.

Total revenues and income for the third quarter of 2026 were $78.7 million, compared with $115.5 million for the prior-year period, representing a decrease of 32%. The prior-year period included $53.1 million of Pelthos divestiture-related income (see Pelthos note below). Excluding that income, total revenues and income increased 26%. Captisol® sales were $7.9 million, compared with $10.7 million, reflecting the timing of customer orders. Contract revenue and income were $0.5 million, compared with $58.2 million, with the decrease primarily due to the prior-year Pelthos divestiture-related income.

Cost of Captisol was $2.7 million for the third quarter of 2026, compared with $3.8 million for the prior-year period, with the decrease primarily attributable to lower Captisol sales. Amortization of intangibles was $10.2 million, compared with $8.1 million for the prior-year period, with the increase attributable to the intangibles acquired from the XOMA acquisition. Research and development expense was $2.8 million, compared with $21.0 million for the prior-year period, with the decrease primarily attributable to a $17.8 million charge recognized in the prior-year period related to the research and development funding arrangement associated with the AVIM Therapy royalty rights acquired in the Orchestra BioMed transaction. General and administrative expense was $72.6 million, compared with $28.4 million for the prior-year period. The increase primarily reflects transaction and integration costs and share-based compensation associated with the XOMA acquisition, as well as higher employee-related costs from the expansion of Ligand’s portfolio management and origination platform to scale its royalty portfolio. Fair value adjustments to contingent liabilities resulted in a $6.3 million loss in the third quarter of 2026, compared with a $0.5 million gain in the prior-year period. The change was primarily driven by fair value adjustments related to contingent liabilities assumed in the XOMA acquisition.

Net non-operating expense was $28.3 million for the third quarter of 2026, compared with net non-operating income of $85.8 million for the prior-year period. The change was primarily attributable to non-cash mark-to-market losses on equity-method investments and other investments, as well as net loss from short-term investments during the third quarter of 2026, compared with gains in the prior-year period.

GAAP net loss was $28.5 million, or $1.43 per share, for the third quarter of 2026, compared with GAAP net income of $117.3 million, or $5.68 per diluted share, for the prior-year period. Results for the third-quarter of 2026 included $39.5 million of pre-tax losses, consisting of a $35.7 million loss from changes in the fair value of equity-method and other investments and a $3.8 million net loss on short-term investments.

Adjusted net income was $57.5 million, or $2.67 per diluted share, compared with $63.8 million, or $3.09 per diluted share, for the prior-year period, representing decreases of 10% and 14%, respectively. The decreases were primarily attributable to the $24.5 million of Pelthos out-license income recognized in the prior-year period (see Pelthos note below) and higher general and administrative expense excluding share-based compensation and transaction and integration costs, partially offset by the 51% increase in royalty revenue. Adjusted net income is a non-GAAP financial measure. See the table below for a reconciliation of GAAP net (loss) income to adjusted net income.

Pelthos note: Prior-year results included $53.1 million of income related to Pelthos. Of that, $24.5 million was attributable to the Zelsuvmi out-license and was included in core revenues, and the $28.6 million gain on the sale was excluded. Growth rates that exclude this income compare the periods on a like-for-like basis.

Year-to-Date Financial Results

Royalty revenue for the nine months ended September 30, 2026 increased 46% to $161.3 million, compared with $110.5 million for the prior-year period, and accounted for 83% of total revenues and income. Royalty growth was primarily driven by the newly acquired XOMA assets and continued momentum across Ligand’s key commercial portfolio, including Travere Therapeutics’ Filspari and Merck’s Ohtuvayre. Total revenues and income were $194.2 million, compared with $208.4 million, representing a decrease of 7%. The prior-year period included $53.1 million of Pelthos divestiture-related income (see Pelthos note above). Excluding that income, total revenues and income increased 25%. Captisol sales were $24.6 million, compared with $32.4 million, reflecting the timing of customer orders. Contract revenue and income were $8.3 million, compared with $65.5 million, with the decrease primarily due to the prior-year Pelthos divestiture-related income.

Cost of Captisol for the nine months ended September 30, 2026 was $9.1 million, compared with $11.6 million for the prior-year period, with the decrease primarily attributable to lower Captisol sales. Amortization of intangibles was $26.4 million, compared with $24.6 million for the prior-year period, with the increase attributable to the intangibles acquired from the XOMA acquisition. Research and development expense was $19.6 million, compared with $77.7 million for the prior-year period, reflecting several prior-year charges: $44.3 million for the research and development funding arrangement associated with the D-Fi royalty rights acquired in the Castle Creek transaction, $17.8 million for the arrangement associated with the AVIM Therapy royalty rights acquired in the Orchestra BioMed transaction, and $6.4 million related to Ligand’s former Pelthos business. This was partially offset by $12.3 million of research and development funding arrangement expense recognized in the current-year period related to Orchestra BioMed. General and administrative expense was $122.6 million, compared with $67.4 million for the prior-year period. The increase primarily reflects transaction and integration costs and share-based compensation associated with the XOMA acquisition, as well as higher employee-related costs, including increased headcount, from the expansion of Ligand’s portfolio management and origination platform to scale its larger royalty portfolio.

Net non-operating expense was $14.7 million for the nine months ended September 30, 2026, compared with net non-operating income of $76.5 million for the prior-year period. The change was primarily attributable to non-cash mark-to-market losses on equity-method investments and other investments during the nine months ended September 30, 2026, compared with non-cash gains recognized in the prior-year period, partially offset by higher gains on short-term investments and higher net interest income.

GAAP net income was $6.7 million, or $0.31 per diluted share, for the nine months ended September 30, 2026, compared with $79.7 million, or $3.95 per diluted share, for the prior-year period. Results for the nine months ended September 30, 2026 included a $49.2 million pre-tax, non-cash loss from change in fair value of equity-method investments and other investments.

Adjusted net income was $142.9 million, or $6.67 per diluted share, compared with $122.4 million, or $6.07 per diluted share, for the prior-year period, representing year-over-year increases of 17% and 10%, respectively. The increase was primarily attributable to the 46% increase in royalty revenue, higher net interest income and realized gains on short-term investments, partially offset by higher general and administrative expense. Adjusted net income is a non-GAAP financial measure. See the table below for a reconciliation of GAAP net (loss) income to adjusted net income.

Adjusted Financial Measures

Ligand reports adjusted net income and adjusted earnings per diluted share in addition to, and not as a substitute for, financial measures calculated in accordance with GAAP, and does not consider such measures superior to GAAP results. The Company also reports “core” versions of these measures, which exclude any gains on the sale of the Pelthos business.

Adjusted earnings per diluted share is a key component of the financial metrics utilized by the Company’s board of directors to evaluate management performance and determine certain elements of management compensation. GAAP results include items such as share‑based compensation expense, amortization of acquisition‑related and intangible assets, changes in contingent liabilities, mark‑to‑market adjustments on investments in public companies, transaction‑related costs and related tax effects, which are excluded from adjusted results and are detailed in the reconciliations included at the end of this press release.

This press release includes adjusted total revenues and income, which excludes all $53.1 million of Pelthos-related income recognized in the prior-year period, including the portion attributed to out-license fees. Ligand believes the adjusted total revenues and income is a more meaningful indicator of its business performance than the GAAP total revenues and income.

Liquidity and Capital Resources

As of September 30, 2026, Ligand had cash, cash equivalents, and short-term investments of $447.4 million, compared with $733.5 million at December 31, 2025. The decrease was primarily driven by cash used for the XOMA acquisition, partially offset by the proceeds from the Company’s issuance of its convertible senior notes due 2031. As of September 30, 2026, including its equity investments and availability under its credit facility, Ligand has approximately $750 million of deployable capital available to pursue additional royalty acquisitions and strategic investments.

2026 Financial Guidance

Ligand is raising its 2026 full year adjusted earnings per diluted share guidance and reaffirming its 2026 revenue guidance. Ligand now expects the following:

  • Royalty revenue of $225 million to $250 million (unchanged)
  • Captisol sales of $35 million to $40 million (unchanged)
  • Contract revenue of $10 million to $20 million (unchanged)
  • Total revenue of $270 million to $310 million (unchanged)
  • Adjusted earnings per diluted share2 of approximately $9.50 to $9.75, raised from approximately $9.00 to $9.50

Third Quarter Corporate Highlights

On July 14, 2026, Ligand completed the acquisition of XOMA Royalty, a biotechnology royalty aggregator. The acquisition strengthens Ligand’s royalty portfolio by adding seven commercial products, including Roche’s VABYSMO® (faricimab-svoa), Servier and Ipsen’s OJEMDA™ (tovorafenib), and Zevra Therapeutics’ MIPLYFFA® (arimoclomol). Additionally, the acquisition adds 14 late-stage development programs, featuring Takeda’s mezagitamab and certain assets from Takeda’s externalized asset portfolio, including osavampator, volixibat, and OHB-607, along with more than 100 additional assets in various stages of development to Ligand’s portfolio. As a result, Ligand’s portfolio has more than doubled in size, now comprising over 200 commercial, clinical, and preclinical stage royalty assets.

On September 22, 2026, Ligand announced the acquisition of a milestone and royalty interest in Santen Pharmaceutical’s Ryjunea from Sydnexis for a $23 million upfront payment. Under the terms of the agreement, Ligand acquired a 100% interest in certain payments and related rights under Sydnexis’s existing license agreement with Santen. The acquired payment rights include a tiered low-double-digit to high-teens royalty on Ryjunea net sales in Europe, the Middle East and Africa, as well as certain milestone payments.

On September 24, 2026, Ligand announced it entered into a financing agreement with AvenCell Therapeutics, Inc., a clinical-stage cell therapy company developing controllable, allogeneic CAR-T therapies for patients with cancer, for up to $47 million. The investment is expected to help advance AvenCell’s pipeline, including AVC-201 for the treatment of relapsed/refractory acute myeloid leukemia (AML) and AVC-203 for the treatment of B-cell malignancies. Under the terms of the agreement, Ligand has committed up to $41 million in exchange for a mid single-digit to low double-digit royalty on worldwide annual net sales of all current and future AvenCell pipeline assets, with the applicable rate determined based on the total amount ultimately funded. The capital will be funded in four tranches, with the first tranche payable at closing, and the remaining three tranches payable upon achievement of certain predetermined clinical milestones and other specified financing conditions. Ligand has also committed up to $6 million in AvenCell’s concomitant Series C financing.

Key Portfolio Developments

Qtorin rapamycin * On August 4, 2026, Palvella announced that it plans to initiate a Phase 3 trial of Qtorin rapamycin for the treatment of cutaneous venous malformations in the fourth quarter of 2026. Palvella is planning a resubmission to the FDA for Breakthrough Therapy Designation incorporating TOIVA patient interview transcripts and new 24-week data.* On October 28, 2026, Palvella announced the FDA accepted for filing and granted Priority Review of the New Drug Application (“NDA”) for Qtorin rapamycin for the treatment of microcystic lymphatic malformations (“microcystic LMs”). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of February 28, 2027. Palvella is preparing for a potential U.S. commercial launch in the first half of 2027, subject to FDA approval.
AVIM Therapy/VIRTUE SAB * On August 10, 2026, Orchestra BioMed highlighted several recent business updates: * The FDA granted AVIM Therapy a second FDA Breakthrough Device Designation (“BDD”) specific to patients with uncontrolled hypertension despite anti-hypertensive medication who are indicated for a pacemaker. * The Virtue Sirolimus AngioInfusion (“Virtue SAB”) pivotal trial is advancing with further site activations and patient enrollments.* On October 1, 2026, Orchestra BioMed announced it surpassed full enrollment in the BACKBEAT global pivotal trial of AVIM Therapy with 330 patients randomized, exceeding its previously announced target of 316 randomized patients.
Zelsuvmi * On August 13, 2026, Pelthos announced several recent business updates: * 11,925 Zelsuvmi units were dispensed by 4,571 unique prescribers during the second quarter of 2026, representing a 48% quarter-over-quarter increase. * More than 25,000 patients have now been prescribed Zelsuvmi since it was commercially launched in July 2025. * Pelthos expects to launch Xepi in the first quarter of 2027.
Lasofoxifene * On August 14, 2026, LeonaBio announced it is on track to complete enrollment of approximately 600 patients in the Phase 3 Elaine-3 clinical trial evaluating lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated metastatic breast cancer in the fourth quarter of 2026 with topline data expected in the second half of 2027.
Ojemda * On September 16, 2026, Ipsen announced the Japanese Ministry of Health, Labour and Welfare (“MHLW”) approved Ojemda for low-grade glioma harboring a BRAF mutation or fusion gene.
Volixibat * On August 5, 2026, Mirum Pharmaceuticals announced volixibat was granted Breakthrough Therapy Designation for cholestatic pruritus due to primary sclerosing cholangitis (PSC). Additionally, a pre-NDA meeting was held for volixibat in cholestatic pruritus due to PSC and additional discussions are planned before potential NDA submission.* On August 5, 2026, Mirum Pharmaceuticals announced enrollment was completed in the VANTAGE Phase 2b study of volixibat in cholestatic pruritus due to primary biliary cholangitis (PBC) with topline results expected in the first quarter of 2027.
Ersodetug * On September 9, 2026, Rezolute provided an update on the FDA’s review of data from its Phase 3 sunRIZE study of ersodetug for hypoglycemia due to congenital hyperinsulinism (“HI”). The study’s open-label extension is ongoing, with high participation and several indicators of improved glycemic control, including a notable reduction in the use of background standard-of-care therapies.* On October 5, 2026, Rezolute announced that following a preliminary review of detailed data from the Phase 3 sunRIZE study of ersodetug for the treatment of hypoglycemia due to congenital HI, the FDA recommended a pre-BLA meeting with Rezolute as a precursor to submitting a BLA.* On October 14, 2026, Rezolute announced completion of enrollment in the Phase 3 study of ersodetug in tumor HI and topline data is expected mid-December 2026.
Soticlestat * On August 13, 2026, Ovid announced a newly formed portfolio company with funds advised by Perceptive Advisors acquired global rights to soticlestat. Ovid secured equity in the company and the potential to receive regulatory and sales milestone payments and royalties upon success. Ligand is entitled to royalties and a share of milestones received by Ovid.
IV ganaxolone * On October 26, 2026, Immedica announced that it will advance the development of intravenous (IV) ganaxolone for the treatment of refractory status epilepticus (RSE) and plans to initiate a new phase 3 clinical study in 2027. Ligand is entitled to royalties, milestones and revenue from Captisol material sales.

**
Conference Call and Webcast**

Ligand management will host a conference call today beginning at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) to discuss its results and answer questions. To participate via telephone, please dial (833) 461-5787 using the conference ID 708822080. International participants outside of Canada may use the toll number +1(585) 542-9983. To participate via live or replay webcast, a link is available at www.ligand.com .

About Ligand Pharmaceuticals

Ligand is a leading royalty aggregator, partnering with biopharmaceutical companies to finance and advance late-stage clinical development programs. Ligand owns and manages one of the largest and most diversified portfolios of biopharmaceutical royalties in the industry, with economic interests in more than 200 development and commercial-stage assets. Ligand funds high-value programs in exchange for long-term economic interests, aligning capital with clinical and commercial success. Ligand’s royalty portfolio is designed to deliver consistent and predictable revenue streams across a broad range of therapeutic assets. Ligand also licenses its proprietary technologies, Captisol® and NITRICIL™, to support drug development and formulation across its global partner network. For more information, visit www.ligand.com or follow Ligand on X and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements, as defined in Section 21E of the Securities Exchange Act of 1934, regarding Ligand’s current expectations. All statements, other than statements of historical fact, could be deemed to be forward-looking statements. In some instances, words such as “plans,” “believes,” “expects,” “anticipates,” and “will,” and similar expressions, are intended to identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect our good faith beliefs (or those of the indicated third parties) and speak only as of the date hereof. These forward-looking statements include, without limitation, Ligand’s ability to expand its portfolio with life sciences royalty opportunities; the timing of clinical and regulatory events of Ligand’s partners and other commercialization and marketing efforts; the timing of the initiation or completion of preclinical studies and clinical trials by Ligand and its partners; the timing of product launches by Ligand or its partners; and guidance regarding projected 2026 financial results. Actual events or results may differ from Ligand’s expectations due to risks and uncertainties inherent in Ligand’s business, including, without limitation: Ligand relies on collaborative partners for milestone payments, royalties, materials revenue, contract payments and other revenue projections and may not receive expected revenue; royalty revenue and income for partners that had not reported product sales as of the date of this press release are based on estimates that may differ from actual results and if such results differ they will be adjusted in future periods; Ligand may not receive expected revenue from Captisol material sales; Ligand and its partners may not be able to timely or successfully advance any product(s) in its internal or partnered pipeline or receive regulatory approval and there may not be a market for the product(s) even if successfully developed and approved; Ligand may not achieve its financial guidance for 2026; Ligand faces competition in acquiring royalties and locating suitable royalties to acquire; Ligand may not be able to create future revenues and cash flows through the acquisition of royalties or by developing innovative therapeutics; products under development by Ligand or its partners may not receive regulatory approval; the total addressable market for our partners’ products may be smaller than estimated; Ligand faces competition with respect to its technology platforms which may demonstrate greater market acceptance or superiority; Ligand is currently dependent on a single source supplier for Captisol and failures by such supplier may result in delays or inability to meet the Captisol demands of its partners; Ligand’s partners may change their development focus and may not execute on their sales and marketing plans for marketed products for which Ligand has an economic interest; Ligand’s collaboration partners may become insolvent; Ligand’s and its partners’ products may not be proved to be safe and efficacious and may not perform as expected and uncertainty regarding the commercial performance of such products; Ligand or its partners may not be able to protect their intellectual property and patents covering certain products and technologies may be challenged or invalidated; cyber-attacks or other failures in telecommunications or information technology systems could result in information theft, data corruption and significant disruption to Ligand’s business operations; Ligand’s partners may terminate any of their agreements or the development or commercialization of any of its products; Ligand and its partners may experience delays in the commencement, enrollment, completion or analysis of clinical testing for its product candidates, or significant issues regarding the adequacy of its clinical trial designs or the execution of its clinical trials, challenges, costs and charges associated with integrating acquisitions with Ligand’s existing businesses; Ligand may not be able to successfully implement its strategic growth plan and continue the development of its proprietary programs; restrictions under Ligand’s credit agreement may limit its flexibility in operating its business and a default under the agreement could result in a foreclosure of the collateral securing such obligations; Ligand may not realize the anticipated benefits from investments in financing instruments such as convertible notes, including the 2031 Notes; Ligand may not successfully integrate the XOMA portfolio or realize the anticipated benefits of the XOMA acquisition; and changes in general economic conditions, including as a result of war, conflict, epidemic diseases, the imposition and/or announcement of tariffs and ongoing or future litigation could expose Ligand to significant liabilities and have a material adverse effect on the Company. The failure to meet expectations with respect to any of the foregoing matters may reduce Ligand’s stock price. Additional information concerning these and other risk factors affecting Ligand can be found in prior press releases available at www.ligand.com as well as in Ligand’s public periodic filings with the Securities and Exchange Commission available at www.sec.gov. Ligand disclaims any intent or obligation to update these forward-looking statements beyond the date of this release, including the possibility of additional license fees and milestone revenues we may receive. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Other Disclaimers and Trademarks

The information in this press release regarding certain third-party products and programs, including Lasofoxifene, a LeonaBio product, AVIM Therapy and Virtue SAB, Orchestra products, Filspari, a Travere Therapeutics product, Ohtuvayre and Capvaxive, Merck products, Qtorin rapamycin, a Palvella Therapeutics product candidate, Vabysmo, a Roche product, Ojemda, a Servier and Ipsen product, Miplyffa, a Zevra Therapeutics product, mezagitamab, osavampator and OHB-607, Takeda product candidates, volixibat, a Mirum Pharmaceuticals product candidate, Ryjunea, a Santen product, AVC-201 and AVC-203, AvenCell Therapeutics product candidates, ersodetug, a Rezolute product candidate, soticlestat, an Ovid Therapeutics product candidate, and Zelsuvmi, a Pelthos Therapeutics product, comes from information publicly released by the owners of such products and programs. Ligand is not responsible for, and has no role in, the development of such products or programs.

Ligand owns or has rights to trademarks and copyrights that it uses in connection with the operation of its business including its corporate name, logos and websites. Other trademarks and copyrights appearing in this press release are the property of their respective owners. The trademarks Ligand owns include Ligand, Captisol, NITRICIL and Zelsuvmi. Solely for convenience, some of the trademarks and copyrights referred to in this press release are listed without the®,© and™ symbols, but Ligand will assert, to the fullest extent under applicable law, its rights to its trademarks and copyrights.

References to “Ligand,” the “Company,” “we,” “our” and similar expressions include Ligand Pharmaceuticals Incorporated and our wholly-owned subsidiaries.

October 27, 2026

JUPITER, Fla., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor conferences:

  • UBS Global Healthcare Conference. Management will participate in one-on-one meetings with investors on November 9, 2026 in Palm Beach Gardens.

  • Stifel 2026 Healthcare Conference. Management will participate in a fireside chat on November 10, 2026 at 10:40 a.m. ET in New York.

  • Miami Biotech Collective Summit 2026. Management will participate in one-on-one meetings with investors on November 30, 2026 in Miami.

Investors interested in arranging one-on-one meetings should contact their UBS**,** Stifel, or J.P. Morgan representative.

About Ligand

Ligand is a leading royalty aggregator, partnering with biopharmaceutical companies to finance and advance late-stage clinical development programs. Ligand owns and manages one of the largest and most diversified portfolios of biopharmaceutical royalties in the industry, with economic interests in more than 100 development and commercial-stage assets. Ligand funds high-value programs in exchange for long-term economic interests, aligning capital with clinical and commercial success. Ligand’s royalty portfolio is designed to deliver consistent and predictable revenue streams across a broad range of therapeutic assets. Ligand also licenses its proprietary technologies, Captisol® and NITRICIL™, to support drug development and formulation across its global partner network. For more information, visit www.ligand.com or follow Ligand on X and LinkedIn .

Ligand to Host Investor Day on December 8, 2026 Bull 0 Bear 0 Routine

October 22, 2026

JUPITER, Fla., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its annual Investor Day will take place on Tuesday, December 8, 2026 from 10:30 a.m. to 12:00 p.m. ET at the Harvard Club of New York City at 35 West 44th Street, New York, NY 10036.

The event will include presentations from Ligand CEO Todd Davis, CFO Tavo Espinoza and other members of the Ligand senior management team. Presentations will highlight the company’s strategy, investment activity, royalty portfolio, and long-term financial outlook. Wes Kaupinen, Founder and CEO of Palvella Therapeutics, a Ligand partner, will be a guest speaker at the event and discuss the progress of QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), which is in development for the treatment of microcystic lymphatic malformations, cutaneous venous malformations, clinically significant angiokeratomas, and additional rare disease indications.

A live webcast of the event will be accessible through Ligand’s Investor Relations Events Page . A webcast replay will be available following the conclusion of the event.

Investors and analysts can register for the event here .

About Ligand
Ligand is a leading royalty aggregator, partnering with biopharmaceutical companies to finance and advance late-stage clinical development programs. Ligand owns and manages one of the largest and most diversified portfolios of biopharmaceutical royalties in the industry, with economic interests in more than 200 development and commercial-stage assets. Ligand funds high-value programs in exchange for long-term economic interests, aligning capital with clinical and commercial success. Ligand’s royalty portfolio is designed to deliver consistent and predictable revenue streams across a broad range of therapeutic assets. Ligand also licenses its proprietary technologies, Captisol® and NITRICIL™, to support drug development and formulation across its global partner network. For more information, visit www.ligand.com or follow Ligand on X and LinkedIn .

Prompts

Ligand Pharmaceuticals Incorporated (ticker LGND), listed in United States.

ETFs Holding Ligand Pharmaceuticals Incorporated

ETF Weight in ETF Shares Market value As of
HELX 4.62% 4,085 $ 1.291M Jun 30, 2026
ALIL 2.92% 2,049 $ 600K Nov 18, 2026
CSMD 2.64% 41,620 $ 11.967M Jul 31, 2026
AFSC 2.16% 753 $ 216.518K Jul 31, 2026
FFOX 1.93% 14,704 $ 4.648M Jun 30, 2026
GSC 1.27% 12,445 $ 3.536M Aug 31, 2026
MMSC 1.03% 1,704 $ 514.114K Nov 16, 2026
NBSM 0.93% 3,758 $ 1.068M Aug 31, 2026
RUSC 0.69% 1,745 $ 551.577K Jun 30, 2026
JSML 0.62% 7,791 $ 2.24M Jul 31, 2026
SQLV 0.48% 432 $ 136.551K Jun 30, 2026
SAWS 0.41% 111 $ 31.917K Jul 31, 2026
SEIS 0.19% 3,443 $ 1.088M Jun 30, 2026
AFSM 0.18% 888 $ 267.918K Nov 16, 2026
JMEE 0.18% 17,379 $ 5.106M Nov 17, 2026
DFAS 0.09% 94,385 $ 29.851M Nov 12, 2026
SMDX 0.06% 246 $ 74.221K Nov 17, 2026
VFMO 0.06% 3,785 $ 1.075M Aug 31, 2026
AVIE 0.04% 23 $ 6,939.33 Nov 16, 2026
MSSM 0.03% 718 $ 203.984K Aug 31, 2026
DFAC 0.01% 40,523 $ 12.816M Nov 12, 2026
DCOR 0.01% 15,045 $ 4.758M Nov 12, 2026
DFAU 0.01% 3,926 $ 1.242M Nov 12, 2026
DFUS 0.00% 2,516 $ 795.735K Nov 12, 2026
DFUV 0.00% 176 $ 55.664K Nov 12, 2026
EBI 0.00% 5 $ 1,420.50 Aug 31, 2026
FESM 0.00% 4 $ 1,264.36 Jun 30, 2026